Affinity Asset Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Affinity Asset Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.7M	Sell	374,000 -1,026,000	-73%	-$34.2M	0.57%	52
2026 Q1	$42.2M	Hold	1,400,000	–	–	2.18%	14
2025 Q4	$43.7M	Hold	1,400,000	–	–	2.49%	13
2025 Q3	$28.3M	Hold	1,400,000	–	–	2.46%	13
2025 Q2	$23.5M	Hold	1,400,000	–	–	3.2%	11
2025 Q1	$21.5M	Hold	1,400,000	–	–	2.05%	13
2024 Q4	$30.9M	Hold	1,400,000	–	–	4.14%	6
2024 Q3	$25.2M	Sell	1,400,000 -50,000	-3%	-$875K	3.44%	7
2024 Q2	$23.6M	Buy	1,450,000 +50,000	+4%	+$770K	2.72%	6
2024 Q1	$19.8M	Sell	1,400,000 -500,000	-26%	-$6.3M	2.45%	13
2023 Q4	$19.8M	Sell	1,900,000 -100,000	-5%	-$934K	3.62%	7
2023 Q3	$20.4M	Buy	2,000,000 +400,000	+25%	+$3.72M	5.74%	2
2023 Q2	$12M	Buy	+1,600,000	New	+$13M	4.21%	6

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Affinity Asset Advisors's TEVA Position: Q2 2026 in Review

Affinity Asset Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 73% in Q2 2026, selling an estimated $34.2M and leaving 374,000 shares worth $12.7M. The position accounts for 0.57% of the portfolio, ranked #52.

Affinity Asset Advisors first reported a position in TEVA in Q2 2023 and has held it in 13 quarters since. The position peaked at $43.7M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Affinity Asset Advisors held 374,000 shares of Teva Pharmaceuticals worth $12.7M as of Q2 2026.
Affinity Asset Advisors sold 1,026,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $34.2M.
Teva Pharmaceuticals made up 0.57% of Affinity Asset Advisors's portfolio in Q2 2026, its #52 holding.
Affinity Asset Advisors first reported a position in Teva Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Affinity Asset Advisors's Teva Pharmaceuticals position peaked at $43.7M in Q4 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.